Boston Scientific announced that it will acquire Baylis Medical Company for $1.75 billion.
The acquisition allows Boston Scientific to expand its electrophysiology and structural heart product portfolios by adding Baylis' radiofrequency (RF) NRG and VersaCross transseptal platforms, as well as guidewires, sheaths, and dilators used to support left heart access.
The platforms facilitate transseptal access by using RF energy, a method shown to increase efficiency, and improve the safety and efficacy of transseptal puncture during left heart procedures.
The deal is expected to close in the first quarter of 2022.
